A Targeted Approach to Cancer

Binding Hope with Better Outcomes™

Contact Us

A Targeted Approach to Cancer

Binding Hope with Better Outcomes™

Contact Us

About STAT3 Therapeutics


STAT3 Therapeutics is an early stage oncology-focused company, dedicated to developing and commercializing drugs that target the activated STAT3 molecule. Our unique approach arrests the activity of the STAT3 dimer using a cyclic decoy that binds to the molecule in a way that is both specific and impactful, without significant toxic side effects.

Learn More
 
 
Appears in over 70% of all human cancers

Why STAT3


STAT3 activation increases cancer cell proliferation, promotes immunosuppression, and appears in over 70% of all human cancers.

STAT3 plays an important regulatory role in a variety of cancers and is a key factor in non-cancer diseases, such as autoimmune diseases.

With this in mind, STAT3 Therapeutics’ approach to drug development has a broad applicability, with an initial focus on head and neck cancers.

Learn More

Our Pipeline

Product Indication Stage
 

S3T-001

Head & Neck Squamous Cell Pre-Clinical
1 2 3 4 5 6

S3T-002

Non-Small Cell Lung Cancer Discovery
1 2 3 4 5 6

S3T-003

Glioblastoma Discovery
1 2 3 4 5 6

S3T-004

Melanoma Discovery
1 2 3 4 5 6